SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. management will be presenting a corporate overview at an investor reception during the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD) on Wednesday, September 19, 2007 at 4:30 a.m. PT / 1:30 p.m. CET local time in Amsterdam, Netherlands.
The live presentation will be webcast, and recordings will be made available following the event. The webcast and recording will be accessible through Amylin’s corporate website, located at http://www.amylin.com. To access the live webcasts, please log on to Amylin’s site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
More information about the EASD meeting is available at: http://www.easd.org/.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.
Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner Izzo, Executive Director of Corporate Affairs ofAmylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 7272
Web site: http://www.amylin.com/
